First-in-human, open-label, prospective, non-randomized clinical trial to evaluate the safety of ARI-HER2 (HER2BBz CAR-T cells) in subjects with relapse or refractory HER2-positive metastatic breast cancer.

Funder: ASOCIACION ESPAÑOLA CONTRA EL CANCER

Call: 2023 AECC Estudios Clínicos (ASOCIACION ESPAÑOLA CONTRA EL CANCER)

Of National scope.